Immuneering Corp. (IMRX)
4.07
+0.04
(+0.99%)
USD |
NASDAQ |
Oct 02, 16:00
4.07
0.00 (0.00%)
After-Hours: 20:00
Immuneering Shareholders Equity (Quarterly) : 190.74M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 190.74M |
| March 31, 2026 | 206.52M |
| December 31, 2025 | 218.48M |
| September 30, 2025 | 227.98M |
| June 30, 2025 | 28.94M |
| March 31, 2025 | 41.84M |
| December 31, 2024 | 41.39M |
| September 30, 2024 | 57.72M |
| June 30, 2024 | 66.31M |
| March 31, 2024 | 78.72M |
| December 31, 2023 | 90.58M |
| September 30, 2023 | 104.02M |
| Date | Value |
|---|---|
| June 30, 2023 | 115.10M |
| March 31, 2023 | 97.79M |
| December 31, 2022 | 109.85M |
| September 30, 2022 | 121.89M |
| June 30, 2022 | 133.59M |
| March 31, 2022 | 144.06M |
| December 31, 2021 | 155.98M |
| September 30, 2021 | 158.29M |
| June 30, 2021 | -35.19M |
| March 31, 2021 | -28.53M |
| December 31, 2020 | -22.48M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 1.307B |
| Alnylam Pharmaceuticals, Inc. | 1.354B |
| Savara, Inc. | 143.66M |
| Vericel Corp. | 370.04M |
| Biogen, Inc. | 18.85B |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 202.06M |
| Total Liabilities (Quarterly) | 11.32M |
| Debt to Equity Ratio | 0.0191 |
| Current Ratio | 19.47 |
| Net Debt Paydown Yield | 0.03% |